Herve Lena

Rouen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 16, 2026

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Journal: Oncology and therapy

Published: March 06, 2026

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 03, 2026

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Journal: Oncology and therapy

Published: July 22, 2025

Real-life first-line systemic treatments for metastatic non-small cell lung cancer (mNSCLC) - Data from the KBP-2020-CPHG cohort

Real-life first-line systemic treatments for metastatic non-small cell lung cancer (mNSCLC) - Data from the KBP-2020-CPHG cohort

Journal: Bulletin du cancer

Published: July 07, 2025

Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France.

Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France.

Journal: Respiratory medicine and research

Published: June 26, 2025

MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.

MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.

Journal: Translational oncology

Published: June 09, 2025

Metabolic and cardiovascular disorders with lorlatinib: How to detect and manage them in practice?

Metabolic and cardiovascular disorders with lorlatinib: How to detect and manage them in practice?

Journal: Bulletin du cancer

Published: April 30, 2025

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.

Journal: Future oncology (London, England)

Published: March 25, 2025

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

Journal: ESMO open

Published: February 10, 2025

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.

Journal: Nature medicine

Published: January 27, 2025

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.

Journal: Frontiers in oncology

Published: November 12, 2024

Showing 1-12 of 101

Last Updated: 09/26/2026